Terlipressin - BioVie

Drug Profile

Terlipressin - BioVie

Alternative Names: BIV-201; Glycylpressin; Glypressin; Terlipressin acetate continuous infusion

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioVie
  • Class Antidiuretics; Antihaemorrhagics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ascites
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ascites

Most Recent Events

  • 14 Sep 2017 Chemical structure information added
  • 27 Jul 2017 BioVie files for patent protection for BIV 201 in the treatment of Ascites in Japan
  • 15 Jul 2017 Phase-II clinical trials in Ascites and Cirrhosis (Treatment-experienced) in USA (IV) (NCT03107091)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top